Publications







Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
J Nucl Med 2016 May 14;57(5):708-14. Epub 2016 Jan 14.
Veterans Affairs Hospital, Tennessee Valley VA Healthcare System, Nashville, Tennessee Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, Tennessee Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; and

Localization of Radiolabeled Somatostatin Analogs in the Spleen.
Clin Nucl Med 2016 Feb;41(2):e111-4
From the *Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands; †Department of General and Visceral Surgery, and ‡Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka; §Institute of Pharmacology and Toxicology, Jena University Hospital, Jena; ∥Laboratory of Pathology and Cytology, Zentralklinik Bad Berka, Bad Berka, Germany; and ¶Department of Radiology, Erasmus MC, Rotterdam, the Netherlands.


Analysis of somatostatin receptor 2A immunohistochemistry, RT-qPCR, and in vivo PET/CT data in patients with pancreatic neuroendocrine neoplasm.
Pancreas 2015 May;44(4):648-54
From the *Department of General and Visceral Surgery, Zentralklinik Bad Berka, Bad Berka; †STRATIFYER Molecular Pathology GmbH, Cologne; ‡Laboratory of Pathology and Cytology, Bad Berka; §Department of Nuclear Medicine, University Hospital Charité, Berlin; ∥Department of Pharmacology and Toxicology, Jena University Hospital, Friedrich Schiller University, Jena; and ¶Department of Molecular Radiotherapy and Molecular Imaging, Center for PET, Zentralklinik Bad Berka, Bad Berka, Germany.

First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.
Cancer Biother Radiopharm 2015 May;30(4):152-9
1 THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, ENETS Center of Excellence , Bad Berka, Germany .

Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors.
Eur J Nucl Med Mol Imaging 2015 Jan 2;42(1):5-19. Epub 2014 Oct 2.
Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, 20141, Milan, Italy,

THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.
Ann Transl Med 2014 Jan;2(1)
1 Internal Medicine/Gastroenterology and Endocrinology, Center for Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, Germany ; 2 THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Center for Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, BRD, Germany.

Successful treatment of metastasized pancreatic vasoactive intestinal polypeptide-secreting tumor unresponsive to high-dose octreotide by peptide receptor radionuclide therapy using 90Y DOTATATE.
Clin Nucl Med 2013 Dec;38(12):996-7
From the *Department of Nuclear Medicine, Hospital Clínico Universitario de Valladolid, Valladolid, Spain; and †THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany.

Role of PET/CT in the functional imaging of endocrine pancreatic tumors.
Abdom Imaging 2012 Dec;37(6):1004-20
Department of Bioimaging and Radiological Sciences, Institute of Nuclear Medicine, Agostino Gemelli Hospital, Università Cattolica del Sacro Cuore, Roma, Italy.


Systemic Endoradiotherapy with Carrier-Added 4-[(131)I]Iodo-L-Phenylalanine: Clinical Proof-of-Principle in Refractory Glioma.
Nucl Med Mol Imaging 2011 Dec 16;45(4):299-307. Epub 2011 Nov 16.
Department of Nuclear Medicine, Experimental Nuclear Medicine and Radiopharmacy, University of Würzburg, 97080 Würzburg, Germany.




Phase 3 Trial ofLu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med 2017 01;376(2):125-135
From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.).

OF